Early anti-TNF treatment in pediatric Crohn's disease. Predictors of clinical outcome in a population-based cohort of newly diagnosed patients.

@article{Olbjrn2014EarlyAT,
  title={Early anti-TNF treatment in pediatric Crohn's disease. Predictors of clinical outcome in a population-based cohort of newly diagnosed patients.},
  author={Christine Olbj\orn and Britt Nakstad and Milada Cvancarova Sm{\aa}stuen and Espen Thiis-Evensen and Morten Harald Vatn and G\ori Perminow},
  journal={Scandinavian journal of gastroenterology},
  year={2014},
  volume={49 12},
  pages={1425-31}
}
OBJECTIVE Pediatric Crohn's disease (CD) is often debilitating, with upper gastrointestinal (GI) involvement and complications over time. Treatment with tumor necrosis factor (TNF) blockers can induce and maintain remission. We wanted to evaluate the outcome of patients medically treated for CD to investigate whether clinical, endoscopic and biochemical factors at diagnosis are associated with the early initiation of treatment with the TNF blocker infliximab. MATERIALS AND METHODS Patients… CONTINUE READING

Similar Papers

Loading similar papers…